Arvanitis, LA, Miller, BG.
Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients
with acute exacerbation of schizophrenia: comparison with haloperidol and
placebo. The Seroquel Trial 13 Study Group. Biol
1997; 42: 233–46.
Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M.
Ziprasidone 80 mg/day and 160 mg/day in the acute
exacerbation of schizophrenia and schizoaffective disorder: a 6-week
placebo-controlled trial. Ziprasidone Study Group.
Kane, JM, Woerner, M, Lieberman, J.
Prevalence, incidence, and risk factors.
J Clin Psychopharmacol
1988; 8 (suppl): 52–6.
Marder, SR, Meibach, RC.
Risperidone in the treatment of
schizophrenia. Am J Psychiatry
1994; 151: 825–35.
Potkin, SG, Saha, AR, Kujawa, MJ, Carson, WH, Ali, M, Stock, E, et al.
Aripiprazole, an antipsychotic with a novel mechanism of
action, and risperidone vs placebo in patients with schizophrenia and
schizoaffective disorder. Arch Gen
2003; 60: 681–90.
Tollefson, GD, Sanger, TM.
Negative symptoms: a path analytic approach to a
double-blind, placebo- and haloperidol-controlled clinical trial with
olanzapine. Am J Psychiatry
1997; 154: 466–74.
Gebhardt, S, Hartling, F, Hanke, M, Mittendorf, M, Theisen, FM, Wolf-Ostermann, K, et al.
Prevalence of movement disorders in adolescent patients with
schizophrenia and in relationship to predominantly atypical antipsychotic
treatment. Eur Child Adolesc Psychiatry
2006; 15: 371–82.
Caroff, SN, Mann, SC, Campbell, EC, Sullivan, KA.
Movement disorders associated with atypical antipsychotic
drugs. J Clin Psychiatry
2002; 63 (suppl 4):
Conner, DE, Fletcher, KE, Wood, JS.
Neuroleptic-related dyskinesias in children and
adolescents. J Clin Psychiatry
2001; 62: 967–74.
Extrapyramidal side effects, tardive dyskinesia, and the
concept of atypicality. J Psychiatry
Tardive dyskinesia rates with atypical antipsychotics in
adults: prevalence and incidence. J Clin
2004; 65 (suppl 9):
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al.
Randomized controlled trial of the effect on quality of life
of second- vs first-generation antipsychotic drugs in schizophrenia: Cost
Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS
1). Arch Gen Psychiatry
2006; 63: 1079–87.
Rosenheck, R, Perlick, D, Bingham, S, Liu-Mares, W, Collins, J, Warren, S, et al.
Effectiveness and cost of olanzapine and haloperidol in the
treatment of schizophrenia: a randomized controlled
2003; 290: 2693–702.
Leucht, S, Wahlbeck, K, Hamann, J, Kissling, W.
New generation antipsychotics versus low-potency conventional
antipsychotics: a systematic review and meta-analysis.
2003; 361: 1581–9.
Rochon, PA, Stukel, TA, Sykora, K, Gill, S, Garfinkel, S, Anderson, GM, et al.
Atypical antipsychotics and parkinsonism.
Arch Intern Med
2006; 165: 1882–8.
Second generation antipsychotics.
2002; 162: 90–1.
Evidence-based guidelines for the pharmacological treatment
of schizophrenia: recommendations from the British Association for
Psychopharmacology. J Psychopharmacol
Verdoux, H, Tournier, M, Bégaud, B.
Antipsychotic prescribing trends: a review of
pharmaco-epidemiological studies. Acta Psychiatr
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al.
Effectiveness of antipsychotic drugs in patients with chronic
schizophrenia. N Engl J Med
2005; 353: 1209–23.
Miller, DD, Caroff, SN, Davis, SM, Rosenheck, RA, McEvoy, JP, Saltz, BL, et al.
Extrapyramidal side-effects of antipsychotics in a randomised
trial. Br J Psychiatry
2008; 193: 279–88.
Hugenholtz, GW, Heerdink, ER, Stolker, JJ, Meijer, WE, Egberts, AC, Nolen, WA.
Haloperidol dose when used as active comparator in randomized
controlled trials with atypical antipsychotics in schizophrenia:
comparison with officially recommended doses. J
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P.
Atypical antipsychotics in the treatment of schizophrenia:
systematic overview and meta-regression analysis.
2000; 32: 1371–6.
Lewis, SW, Davies, L, Jones, PB, Barnes, TRE, Murray, RM, Kerwin, R, et al.
Randomised controlled trials of conventional antipsychotic
versus new atypical drugs, and new atypical drugs versus clozapine, in
people with schizophrenia responding poorly to, or intolerant of, current
drug treatment. Health Technol Assess
Henrichs, DW, Hanlon, TE, Carpenter, WT.
The Quality of Life Scale: an instrument for rating the
schizophrenic deficit syndrome. Schizophr
1984; 10: 388–98.
The Barnes Akathisia Rating Scale: revisited.
2003; 17: 365–70.
Simpson, G, Angus, JSW.
A rating scale for extrapyramidal side
effects. Acta Psychiatr Scand Suppl
ECDEU Assessment Manual for Psychopharmacology. Revised
DHEW Pub. (ADM). National Institute for Mental
A Dictionary of Epidemiology (4th edn).
Oxford University Press,
Klawans, HL, Rubovits, R.
Effect of cholinergic and anticholinergic agents on tardive
dyskinesia. J Neurol Neurosurg
1974; 37: 941–7.
Greil, W, Haag, H, Rossnagl, G, Rüther, E.
Effect of anticholinergics on tardive dyskinesia. A
controlled discontinuation study. Br J
1984; 145: 304–10.
Moore, NA, Tye, NC, Axton, MS, Risius, FC.
The behavioral pharmacology of olanzapine, a novel ‘atypical’
antipsychotic agent. J Pharmacol Exp
1992; 262: 545–51.
Lloyd, HM, Markwick, AJ, Page, ER, Lewis, S, Barnes, TRE.
Attitudes to atypical and conventional antipsychotic drug
treatment in clinicians participating in the CUtLASS
study. Int J Psychiatry Clin Pract
Ren, XS, Huang, YH, Lee, AF, Miller, DR, Qian, S, Kazis, L.
Adjunctive use of atypical antipsychotics and anticholinergic
drugs among patients with schizophrenia. J Clin
Open forum: effectiveness versus efficacy of
second-generation antipsychotics: haloperidol without anticholinergics as
a comparator. Psychiatr Serv
Cheng, F, Jones, PB.
Second-generation atypical versus first-generation
conventional antipsychotic drug treatment in schizophrenia: another
triumph of hope over experience? In Therapeutic
Strategies in Schizophrenia (eds Mortimer, A, McKenna, PJ): 193–206. Clinical
Mackin, P, Thomas, SH.
Atypical antipsychotic drugs.